Pfizer stock after-hours at EUR 25.25: minus 0.16 percent versus prior close
Published on 09/29/2026 at 21:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pfizer stock was at EUR 25.25 after-hours at 8:53 p.m. CEST on September 29, 2026, down 0.16 percent versus the prior close at Lang & Schwarz.
Pfizer outlines ESMO oncology program
In a September 28 announcement, FT.com reported that Pfizer Inc. plans to present data from 45 company-sponsored, investigator-sponsored and collaborative research abstracts at the European Society for Medical Oncology Congress in Madrid from October 23 through October 27, 2026. The program includes 11 oral presentations covering established medicines and late-stage pipeline candidates in breast, genitourinary and lung cancers.
The announcement highlighted research involving PADCEV, TALZENNA, atirmociclib and tivunatamig, as well as studies of investigational therapies in lung cancer, breast cancer, bladder cancer, prostate cancer and melanoma.
Third-quarter report scheduled for November 3
Pfizer said in a September 22 press release that it will hold a conference call with analysts on November 3, 2026, to discuss its third-quarter 2026 performance report, which the company plans to issue that morning.
